Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Periscope Analytics

Periscope Analytics focuses on event-driven trades across Asia Pacific and provides comprehensive, timely and systematic coverage of index changes to major Asia Pacific indices in a structured manner.

The analysis includes forecasted inclusions and exclusions to all major Asian indices that have significant amount of tracking assets, including estimates of passive buy/sell flow on the stocks. The service also provides commentary and impact of market consultations, ground rule changes, and other events (IPOs, spin-offs, M&A) that could lead to index changes and passive flow.

Periscope Analytics works with multi-strategy hedge funds, proprietary trading firms, stat arb trading groups and long-only investors that invest and trade in the Asia Pacific region with the data being used to trade index rebalances, avoid pre-positioning and passive flow, and to time entry into and exit from stocks.

Event-Driven Trades Across Asia Pacific

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mankind-pharma-ltd" target="_blank" data-smartkarma-citation="entities:36389:1" rel="noopener">Mankind Pharma (6596876Z IN)</a> is looking to raise up to US$526m in its IPO by selling 40.06m shares at a price range of INR 1026 to INR 1080 per share.</li>
<li>The company has allocated 12.02m shares to anchor investors at INR 1080/share. That list includes marquee names and the lock-up reduces near-term float.</li>
<li>The IPO opens on 25 April and will close on 27 April. Shares are expected to start trading on 9 May and there are no near-term index inclusions expected.</li>
</ul>



Mankind Pharma (6596876Z IN) is looking to raise up to US$526m in its IPO by selling 40.06m shares at a price range of INR 1026 to INR 1080 per share.
The company has allocated 12.02m shares to anchor investors at INR 1080/share. That list includes marquee names and the lock-up reduces near-term float.
The IPO opens on 25 April and will close on 27 April. Shares are expected to start trading on 9 May and there are no near-term index inclusions expected.


Mankind Pharma: IPO Details & Index Inclusion

<ul>
<li>The lock-up on nearly 9.4bn shares of <a href="https://www.smartkarma.com/entities/yes-bank-ltd" target="_blank" data-smartkarma-citation="entities:767:1" rel="noopener">Yes Bank (YES IN)</a> expires on 13 March. Most of that is from the banks that helped in the recapitalisation in March 2020.</li>
<li>There will be forced sellers as soon as the lock-up ends, and there will be other sellers that will want to sell.</li>
<li>The forced and discretionary selling will be offset to a very small extent by inflows from passive trackers in May/June as the free float for the stock increases.</li>
</ul>


The lock-up on nearly 9.4bn shares of Yes Bank (YES IN) expires on 13 March. Most of that is from the banks that helped in the recapitalisation in March 2020.
There will be forced sellers as soon as the lock-up ends, and there will be other sellers that will want to sell.
The forced and discretionary selling will be offset to a very small extent by inflows from passive trackers in May/June as the free float for the stock increases.


YES Bank Lock-Up Expiry: Forced Sellers, Overhang & Index Implications

Chief Economist & Political Strategist, CrossASEAN Research

Prasenjit K. Basu

Chief Economist & Political Strategist

CrossASEAN Research

At CrossASEAN Research we strive to produce unbiased and differentiated on the ground insights on companies across South East Asia. Our Research is produced for the most part after face to face meetings and conversations with company management to dig deep into the long term vision and strategy of the companies we cover. We seek to deliver investable and actionable themes on sectors and markets across SE Asia, often in collaboration with other Insight Providers across the region, pooling the vast experience of the analysts within the Smartkarma Ecosystem. We also offer bespoke work and tailor made trips for our clients. 

Insights across South East Asia

Macroeconomics

<ul>
<li>For a second consecutive year, fiscal policy is mildly contractionary while accommodating a 30%+ hike in public investment. Strong tax revenues help lower the fiscal deficit by 0.5% of GDP.</li>
<li>Surging nominal GDP boosted corporate &amp; income tax revenue by 16%YoY+ and central GST revenue by 30%YoY in Apr-Dec'22. Actual FY23 deficit will be 6% (rather than 6.4%) of GDP. </li>
<li>We expect nominal GDP to grow 13% (vs 10.4% official projection) in FY24, cutting fiscal deficit to 5.5% of GDP, thus crowding-in private investment, enabling real GDP to grow 7.2%. </li>
</ul>


For a second consecutive year, fiscal policy is mildly contractionary while accommodating a 30%+ hike in public investment. Strong tax revenues help lower the fiscal deficit by 0.5% of GDP.
Surging nominal GDP boosted corporate &amp; income tax revenue by 16%YoY+ and central GST revenue by 30%YoY in Apr-Dec'22. Actual FY23 deficit will be 6% (rather than 6.4%) of GDP. 
We expect nominal GDP to grow 13% (vs 10.4% official projection) in FY24, cutting fiscal deficit to 5.5% of GDP, thus crowding-in private investment, enabling real GDP to grow 7.2%. 


India: Surging Tax Revenue Helps Lower PSBR, Ensuring Capex-Led Growth

<ul>
<li>India's real policy rate was +0.55% in Dec'22, as CPI inflation receded to 5.72%YoY, within the RBI's 2-6% inflation target for the second consecutive month. No more rate hikes likely. </li>
<li>Industrial output expanded 7.1% YoY in Nov'22, with consumer nondurables output up 8.9%YoY -- tentative sign of a turnaround in consumption after a half-year of sluggishness. Consumer durables rebounded too. </li>
<li>After a stagnant decade, capital goods output expanded 20.7%YoY in Nov'22 (+14.9%YoY in Apr-Nov'22), capital goods imports +15.4%YoY. Rebounding GFCF will ensure 7.5% RGDP growth in FY23, 7.2% in FY24.</li>
</ul>


India's real policy rate was +0.55% in Dec'22, as CPI inflation receded to 5.72%YoY, within the RBI's 2-6% inflation target for the second consecutive month. No more rate hikes likely. 
Industrial output expanded 7.1% YoY in Nov'22, with consumer nondurables output up 8.9%YoY -- tentative sign of a turnaround in consumption after a half-year of sluggishness. Consumer durables rebounded too. 
After a stagnant decade, capital goods output expanded 20.7%YoY in Nov'22 (+14.9%YoY in Apr-Nov'22), capital goods imports +15.4%YoY. Rebounding GFCF will ensure 7.5% RGDP growth in FY23, 7.2% in FY24.


India: Growth on Track Even as Inflation Abates; No More Rate Hikes Likely

<ul>
<li>End December was the end of the review cutoff for a lot of indices that will rebalance within the next couple of months.</li>
<li>
<a href="https://www.smartkarma.com/entities/pexa-group-ltd" target="_blank" data-smartkarma-citation="entities:34716:1" rel="noopener">PEXA Group (PXA AU)</a> replaces <a href="https://www.smartkarma.com/entities/pendal-group-ltd" target="_blank" data-smartkarma-citation="entities:15795:1" rel="noopener">Pendal Group (PDL AU)</a> in the <a href="https://www.smartkarma.com/entities/s-p-asx-200" target="_blank" data-smartkarma-citation="entities:22901:1" rel="noopener">S&amp;P/ASX 200 (AS51 INDEX)</a> at the close on 12 January.</li>
<li>There were big outflows from Hong Kong and China focused ETFs led by <a href="https://www.smartkarma.com/entities/hang-seng-china-enterprises-index-etf" target="_blank" data-smartkarma-citation="entities:25:1" rel="noopener">Hang Seng H Share Index ETF (2828 HK)</a> and <a href="https://www.smartkarma.com/entities/tracker-fund-of-hong-kong-ltd" target="_blank" data-smartkarma-citation="entities:29257:1" rel="noopener">Tracker Fund of Hong Kong Ltd (2800 HK)</a>.</li>
</ul>


End December was the end of the review cutoff for a lot of indices that will rebalance within the next couple of months.

PEXA Group (PXA AU) replaces Pendal Group (PDL AU) in the S&amp;P/ASX 200 (AS51 INDEX) at the close on 12 January.
There were big outflows from Hong Kong and China focused ETFs led by Hang Seng H Share Index ETF (2828 HK) and Tracker Fund of Hong Kong Ltd (2800 HK).


Index Rebalance & ETF Flow Recap: HSCEI, HSTECH, HSI, HSCI, KS200, KQ150, CSI300, SENSEX, LQ45, PSEi

India

The S&P BSE Sensex Index is a cap-weighted index. The index members have been selected on the basis of liquidity, depth, and floating-stock-adjustment depth and industry representation. Sensex has a base date and value of 100 in 1978-1979. The Index shifted to free-float methodology since 09/01/03. Please see {SNSXOLD Index <GO>} for mid-month options.

S&P BSE SENSEX Index (SENSEX INDEX EQUITY)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

S&P BSE SENSEX Index (SENSEX INDEX EQUITY)

Mankind Pharma: IPO Details & Index Inclusion

Mankind Pharma is looking to raise up to US$526m in its IPO by selling 40.06m shares at INR 1080/share. 12.02m shares have been allocated to anchor...

Brian Freitas

YES Bank Lock-Up Expiry: Forced Sellers, Overhang & Index Implications

Over 9bn shares of YES Bank unlock next week. There will be forced selling from local passive trackers, overhang from the banks that helped recap...

Brian Freitas

India: Surging Tax Revenue Helps Lower PSBR, Ensuring Capex-Led Growth

CGST revenue up 30%YoY & income taxes 16%YoY in Apr-Dec'22, enabling 33% boost to public investment for FY24 but still lowering the fiscal deficit....

Prasenjit K. Basu

India: Growth on Track Even as Inflation Abates; No More Rate Hikes Likely

Real policy rate of +0.55% ensures no rate hikes are likely this year, as food & energy inflation recede. Rebounding capital goods output & imports...

Prasenjit K. Basu

Index Rebalance & ETF Flow Recap: HSCEI, HSTECH, HSI, HSCI, KS200, KQ150, CSI300, SENSEX, LQ45, PSEi

This recap highlights Insights covering Asian index rebalances (announcements/ forecasts/ IPO Fast Entry/ M&A driven changes). We also highlight...

Brian Freitas

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)